Lung Therapeutics announced that the Food & Drug Administration (FDA) has granted Orphan Drug designation to its lead drug candidate, LTI-01 for the treatment of empyema, a typical complication of pneumonia.

LTI-01 is an injectable, fibronolytic drug that maximizes scar removal around the lungs, thus promoting fluid drainage while minimizing bleeding risk and other complications.

RELATED: Community Acquired Pneumonia Guidelines

Lung Therapeutics currently has pipeline programs ongoing in three areas, LTI-01 in loculated pleural effusion (PE), LTI-02 in acute lung injury (ALI), and LTI-03 in idiopathic pulmonary fibrosis (IPF). LTI-03 has been shown to reverse belomycin-induced lung injury when given at seven or 14 days after induction of injury, and is currently being studied in additional tests.

For more information call (512) 872-7527 or visit LungTx.com.